Effect of Empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes patients with heart failure with reduced ejection fraction

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211219053450N1

Enrollment

112

Registered

2022-06-05

Start date

2022-07-16

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure. Heart failure, unspecified

Interventions

Intervention 1: Intervention group: Impagliflozin drug at a dose of 10 mg is administered once a day for 36 weeks. Intervention 2: Control group: Patients in the control group receive placebo.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus (HbA1C= 6.5%) or pre-diabetes (HbA1c between 5.7% to 6.4%) and ischemic heart failure with reduced fractional ejection (LVEF = 40%) over 18 years old Functional NYHA Class II to IV Patient consent for participation in research

Exclusion criteria

Exclusion criteria: Type 1 diabetes; Severe liver failure; eGFR <mL / min / 1.73m2 30; History of diabetic ketoacidosis; Existence of any malignancy and cancer; Lack of adherence to the treatment regimen.

Design outcomes

Primary

Measure	Time frame
Left ventricular volumes. Timepoint: before and 6 months after intervention. Method of measurement: Echocardiographic parameters.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactOmid Sherafat

Ahvaz University of Medical Sciences

omidsherafat70@gmail.com+98 61 3222 8037

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026